Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer
Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer
Phase 1 Study Supports Recommended Phase 3 Dose for Investigational EGFR x HER3 Antibody-Drug Conjugate in EGFR-Mutated Lung Cancer
NASA Awards First Prize in Phase 2 of Agency’s LunaRecycle Challenge
Insilico Medicine announces oral presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in mesothelioma and advanced solid tumors - EurekAlert!
Holographic 3D printing with phase light modulators boosts efficiency 70? —and enables multi-scale printing - EurekAlert!
Reversible optical data storage and encryption enabled by phase-change and hydrogel integration - EurekAlert!
Multimodal imaging: A highly integrated fluorescence-phase microscopy system - EurekAlert!
A phase I-II study of niacin in patients with newly diagnosed glioblastoma: safety and interim phase II analysis
Insilico completes first-in-human dosing in phase I clinical study of AI-driven NLRP3 inhibitor ISM8969, achieving first clinical milestone in collaboration with Hgtia - EurekAlert!
World first: First phase 3 trial of in vivo CRISPR therapy successfully completed CRISPR treatment comes one step closer to reality - EurekAlert!
World first: First phase 3 trial of in vivo CRISPR therapy successfully completed CRISPR treatment comes one step closer to reality - EurekAlert!
Phase 1 clinical trial set to begin on first leishmaniasis vaccine - EurekAlert!
RAS(ON) inhibitor doubles median overall survival in results of phase 3 trial for patients with metastatic pancreatic cancer - EurekAlert!
